India's anti-obesity drug market has grown more than fourfold in the last five years

India's anti-obesity drug market has surged, growing over fourfold in five years, reaching ₹576 crore by March 2025, driven by lifestyle diseases and increased affordability. Semaglutide, particularly Rybelsus from Novo Nordisk, dominates the market, accounting for 69% of sales. The introduction of Mounjaro by Eli Lilly has further fueled acceptance, with Novo Nordisk planning to launch Wegovy soon.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kH4dnYr
via IFTTT